FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company
CardioComm Solutions, Inc.
259 Yorkland Road, Suite 200
North York, ON M2J 0B5

2. Date of Material Change
July 3, 2015

3. News Release
The news release announcing the material change was disseminated on July 6, 2015, through Transmedia Industries. The news release was also filed with the British Columbia, Alberta and Ontario Securities Commissions on SEDAR.

4. Summary of Material Change
CardioComm Solutions granted 1,050,060 incentive stock options to members of its board of directors. 250,060 of the options are exercisable at $0.144 per share for five years from the date of grant and vest immediately, 250,000 of the options are exercisable at $0.14 per share for five years from the date of grant and vest on November 3, 2015, and 550,000 of the options are exercisable at $0.14 per share for five years from the date of grant and vest on December 31, 2015.

5.1 Full Description of Material Change
See attached news release.

5.2 Disclosure for Restructuring Transactions
N/A

6. Reliance on subsection 7.1(2) of National Instrument 51-102
Not applicable.

7. Omitted Information
No information has been intentionally omitted from this material change report.

8. Executive Officer
Etienne Grima, CEO, 1-877-977-9425

9. Date of Report
July 7, 2015

CardioComm Solutions, Inc.

PRESS RELEASE

FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

July 6, 2015

CARDIOCOMM SOLUTIONS ISSUES STOCK OPTIONS

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of ECG acquisition and management software solutions, today announced that it has granted an aggregate of 1,050,060 incentive stock options to members of its board of directors. 250,060 of the options are exercisable at $0.144 per share for five years from the date of grant and vest immediately, 250,000 of the options are exercisable at $0.14 per share for five years from the date of grant and vest on November 3, 2015, and 550,000 of the options are exercisable at $0.14 per share for five years from the date of grant and vest on December 31, 2015. The grant of options is subject to the provisions of the Company's Stock Option Plan, the policies of the TSX Venture Exchange and applicable securities laws.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada, with offices in Victoria, B.C.

FOR FURTHER INFORMATION PLEASE CONTACT:
Etienne Grima, Chief Executive Officer
1-877-977-9425
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*).